Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy.
Patel S.
J Steroid Biochem Mol Biol. 2018 Sep;182:27-36. doi: 10.1016/j.jsbmb.2018.04.008. Epub 2018 Apr 17.
Endocrine toxicities of immune checkpoint inhibitors.
Wright JJ, Powers AC, Johnson DB.
Nat Rev Endocrinol. 2021 Jul;17(7):389-399. doi: 10.1038/s41574-021-00484-3. Epub 2021 Apr 19.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM.
JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064.
Oncocrinology.
Kalra S, Priya G, Bhattacharya S, Sahay R.
J Pak Med Assoc. 2020 Apr;70(4):757-761.
The theory of tumor ecosystem.
Chen X, Song E.
Cancer Commun (Lond). 2022 Jul;42(7):587-608. doi: 10.1002/cac2.12316. Epub 2022 Jun 1.
Effect of Nutritional Supplementation on Oxidative Stress and Hormonal and Lipid Profiles in PCOS-Affected Females.
Dubey P, Reddy S, Boyd S, Bracamontes C, Sanchez S, Chattopadhyay M, Dwivedi A.
Nutrients. 2021 Aug 25;13(9):2938. doi: 10.3390/nu13092938.
The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I, Pandey MR, Sharma R, Chaudhuri A, Dandona P.
Indian J Med Res. 2021 Apr;154(4):559-570. doi: 10.4103/ijmr.IJMR_313_19.
The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
Ramchand SK, Cheung YM, Yeo B, Grossmann M.
J Endocrinol. 2019 Jun 1;241(3):R111-R124. doi: 10.1530/JOE-19-0077.
Endocrine Consequences of Childhood Cancer Therapy and Transition Considerations.
Yu C.
Pediatr Ann. 2019 Aug 1;48(8):e326-e332. doi: 10.3928/19382359-20190729-02.
The pleura and the endocrine system.
Sorino C, Negri S, Spanevello A, Feller-Kopman D.
Eur J Intern Med. 2020 Feb;72:34-37. doi: 10.1016/j.ejim.2019.12.034. Epub 2020 Jan 7.
